Stephens raised the firm’s price target on Natera (NTRA) to $235 from $197 and keeps an Overweight rating on the shares after the company reported “another strong beat.” The firm continues to view Natera as “one of the most attractive organic growth stories” within diagnostics, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA: